Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Rises By 71.6%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 212,357 shares, an increase of 71.6% from the August 15th total of 123,737 shares. Based on an average daily volume of 1,455,508 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company’s shares are short sold.

Analyst Ratings Changes

INDP has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Indaptus Therapeutics Price Performance

Shares of NASDAQ:INDP traded up $0.72 during mid-day trading on Thursday, reaching $3.93. 911,603 shares of the company were exchanged, compared to its average volume of 626,155. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $8.57. The firm’s 50-day simple moving average is $1.78 and its 200 day simple moving average is $2.16. The firm has a market cap of $523.63 million, a price-to-earnings ratio of -0.62 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.